Pharmaceutical Technology reported on Nexo's Series A financing and described how the company's platform combines covalent ligand discovery and chemical biology to pursue previously difficult oncology targets.
The article summarized the role of the CODON chemistry engine in finding and optimizing ligands and underscored the company’s effort to pair chemistry innovation with scalable biological insight. It also noted the participation of Versant Ventures, NEA and Cormorant Asset Management in the financing.
Pharmaceutical Technology reported on Nexo’s Series A financing and described the company as a new small-molecule oncology business using covalent ligand discovery and chemical biology to pursue previously difficult targets. The coverage emphasized that the $60 million round will support the platform behind Nexo’s cancer therapy pipeline.
Original coverage: Pharmaceutical Technology